Technology evaluation: lerdelimumab, Cambridge Antibody Technology.
作者： Cordeiro Mf
DOI:
关键词:
摘要: Cambridge Antibody Technology is developing lerdelimumab (CAT-152), the lead in a series of human anti-TGF beta 2 antibodies, for its potential preventing post-operative scarring patients undergoing surgery glaucoma (trabulectomy). It also has treatment fibrosis, cataract, retinopathy and connective tissue disease.
参考文章(0)